Concept
Reprogrammation épigénétique
Personnes associées (23)
Didier Trono
Après des études de médecine à l’Université de Genève et une formation clinique en pathologie, médecine interne et maladies infectieuses à Genève et au Massachusetts General Hospital de Boston, Didier Trono s’engage dans une carrière scientifique au Whitehead Institute du MIT. En 1990, il est recruté par le Salk Institute de San Diego pour lancer un centre de recherche sur le SIDA. Il rentre en Europe sept ans plus tard, avant de prendre en 2004 les rênes de la toute nouvelle faculté des Sciences de la Vie de l’EPFL, dont il orchestre le développement et qu’il dirige jusqu’en 2012. Il participe aujourd’hui activement à la coordination des efforts de la Suisse en vue de l’intégration des nouvelles technologies dans le domaine de la médecine de précision et de la santé personnalisée.
Priscilla Turelli
Positions
2005-présent: Chercheur, Ecole Polytechnique Fédérale de Lausanne, Laboratoire de virologie et génétique, Suisse.
2001-2004: Chercheur dans le laboratoire du Pr D. Trono, Département de Microbiologie, Ecole de Médecine de Genève, Suisse.
1997-2001: Etudiante Post-doctorante dans le laboratoire du Pr D. Trono, Département de Microbiologie, Ecole de Médecine de Genève, Suisse.
Honneurs et prix 2004: Bristol-Myers Squibb AIDS AWARD 1997-1999: Human Frontier Science Program fellowship
Education June 1997: PhD in cellular biology. Final mark:jury congratulations. Université de la Méditerranée, France. June 1993: Post-graduate diploma in cellular biology and microbiology. INSERM U372, Marseille-Luminy, université de Provence, France. June 1992: Master in cellular biology Specialty: genetic. Final mark: Best master student of this year. Université de la Méditerranée, France. June 1987: Scientific baccalaureate, France.
Enseignement 2009-présent: co-directeur de thèses, Ecole Polytechnique Fédérale de Lausanne, Suisse 2002: Tuteur en virologie pour les étudiants de médecine, Ecole de Médecine de Genève, Suisse. 1996-1997: Tuteur en biologie moléculaire et biochimie, Université de la Méditerranée, Aix Marseille II
Honneurs et prix 2004: Bristol-Myers Squibb AIDS AWARD 1997-1999: Human Frontier Science Program fellowship
Education June 1997: PhD in cellular biology. Final mark:jury congratulations. Université de la Méditerranée, France. June 1993: Post-graduate diploma in cellular biology and microbiology. INSERM U372, Marseille-Luminy, université de Provence, France. June 1992: Master in cellular biology Specialty: genetic. Final mark: Best master student of this year. Université de la Méditerranée, France. June 1987: Scientific baccalaureate, France.
Enseignement 2009-présent: co-directeur de thèses, Ecole Polytechnique Fédérale de Lausanne, Suisse 2002: Tuteur en virologie pour les étudiants de médecine, Ecole de Médecine de Genève, Suisse. 1996-1997: Tuteur en biologie moléculaire et biochimie, Université de la Méditerranée, Aix Marseille II
Matthias Lütolf
Matthias Lutolf is Full Professor at EPFL’s Institute of Bioengineering, with a cross appointment in the Institute of Chemical Sciences and Engineering. Lutolf was trained as a Materials Engineer at ETH Zurich where he also carried out his PhD studies (with Jeffrey Hubbell) that were awarded with an ETH medal. He continued his research training as a Post-Doctoral Fellow in Stem Cell Biology (with Helen Blau) at Stanford University. He has served as the Director of the Institute of Bioengineering from 2014 to 2018. Lutolf is an internationally recognized leader in the fields of stem cell bioengineering and tissue engineering. His research program uniquely combines stem cell biology with engineering principles and quantitative thinking. His team, composed of engineers, chemists, physicists, cell and developmental biologists, strives to develop technologies that have true biological and medicinal function and applicability. Lutolf’s work has led to more than 110 peer-reviewed scientific publications, many of which published in highly reputed journals, more than 25 patents, and the commercialization of several products. Current research in the Lutolf lab is focused on the bioengineering of miniature tissues, termed organoids, that are generated from self-organizing stem cells.
Yann Barrandon
Yann Barrandon graduated in Medicine in Paris where he also trained as a dermatologist and completed his PhD on the long term cultivation of human haematopoietic stem cells in 1982 under the direction of Dr. Catherine Dresch (Centre Hayem, St Louis Hospital). He worked as a post-doctoral fellow (1982-1983) with Pr. Marvin Karasek in the Department of Dermatology at Stanford University CA, and then with Pr. Howard Green, a pioneer in cell therapy, in the Department of Molecular and Cellular Physiology at Harvard Medical School (1983-1990). During this period, he participated in the world's first transplantations of epidermal stem cells on extensive third degree wounds and contributed several seminal findings including the demonstration of stem cells in cultures of human keratinocytes (PNAS 1987), and that human keratinocyte stem cells could be efficiently transduced by retroviral vectors (Science 1987), in collaboration with Richard Mulligan at the Whitehead Institute for Biomedical Research (Massachussets Institute of Technology, Cambridge, USA). He has also participated to the transfer of the stem cell technology from Harvard University to a spin off biotechnology company, now part of Genzyme Corp.
He returned to France in 1990 as Director of Research at the INSERM and Head of Lab at the Ecole Normale Supérieure, Paris. During this period, he demonstrated the presence of multipotent clonogenic stem cells in hair follicles (Cell 1994, 2001) and successfully brought stem cells from bench to bedside demonstrating the usefulness of a fibrin matrix to transplant epidermal stem cells. (Transplantation, 2000). Following his move to Lausanne, Yann Barrandon has shown that oligopotent stem cells are present in the mammalian cornea (Nature 2008), challenging previous dogma. He has also contributed to the characterisation of several skin diseases (Nature Genetics, 1993a, 1993b, 2000, 2005) and towards gene therapy of dystrophic epidermolysis bullosa. He is a partner in several EEC stem cell consortia (FP6: Therapeuskin and EuroStemCell, FP7: EuroSyStem, OptiStem, BetaCellTherapy).
Current research targets the role of small microenvironmental variations on stem cell behavior, and exploring the potency of stem cells of stratified epithelia (skin, esophagus, ocular surface) and of thymic epithelial cells. The lab is also involved in understanding the factors that regulate stem cell engraftment to improve epithelial cell therapy. An important aspect of the research aims at setting up a pilot clinical trial to demonstrate the feasibility of ex vivo gene therapy to treat Dystrophic Epidermolysis Bullosa, a rare but horrendous congenital disease of the skin that results in continuous blistering of the skin, chronic wounds, fusion of fingers and development of carcinoma.
Yann Barrandon was a member of the Faculty Council of the EPFL School of Life Sciences 2006-2008, of the Board of Swiss Stem Cell Network, 2004-2009, and is a member of the EPFL Ethics Committee since 2008. He is a reviewer for major scientific journals and for major granting agencies abroad. He is a member of the board of Directors of the International Society for Differentiation (ISD) and of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) and was a Member of the Board of Directors of the European Tissue Repair Society, 1990-1995. He was elected as EMBO member in 2009.
He has given over 300 invited conferences and seminars worldwide on the biology and the therapeutic use of cutaneous stem cells including:
Gordon Research Conferences, Tissue Repair and Regeneration, June 2005, New London, USA,
Keystone Symposia on Stem Cells, April 2006, Whistler, Canada
Keystone Symposia, Stem Cell Interactions with their Microenvironmental Niche, March 2007, Keystone, USA
Keystone Symposia, Stem Cell Niche Interactions, April 2009, Whistler, Canada
Gordon Research Conferences, Epithelial Stem Cells, June 2009, Les Diablerets, Switzerland
7th Meeting of the International Society Stem Cell Research, July 2009, Barcelona, Spain
16th International Society for Developmental Biologists, Edinburgh, Scotland, UK, Sept 2009
Yann Barrandon has given multiple media interviews and participated to different reportages:
LCI, TF1, France 2, France 3, RSR (Radio Suisse Romande), TSR (Television Suisse Romande), and articles in newspapers: Figaro, La Croix, Le Temps, LHebdo, Le Nouvelliste, etc. He was also a participant in the movie A Stem Cell Story, EuroStemCell, Best TV/video production, Tromsø Science Media Festival; Best short film, Scinema (Australia); In competition, Science Film Festival (Bangkok), BaKaFORUM 2007, Vedere la Scienza
He organized the second EuroStemCell international conference Advances in Stem Cell Research supported by the EMBO and held in Lausanne 8-10 September 2006. He regularly participates as faculty to the EEC funded Stem Cell Summer School held in Hydra Greece since 2005.
Daniel Constam
Daniel Constam received his doctoral degree in Natural Sciences from ETH Zürich in the neuroimmunology group of Adriano Fontana (1993). For postdoctoral studies, he joined the laboratory of Elizabeth Robertson as an EMBO fellow at Harvard University to characterize proprotein convertase (PC) functions in mouse models of early embryogenesis (1994-1999). As an ISREC group leader (>2000) and Associate Professor at EPFL (>2007), he initially continued to study pluripotency and lineage differentiation during development and found that several secreted PCs jointly regulate cell-cell adhesion and TGFβ signaling pathways at the cross-roads of stem cell and cancer biology. To map the proteolytic activity of PCs and their relative distribution in exocytic or endocytic vesicles, his lab developed PC-specific FRET sensors for high resolution live imaging in normal cells and in tumour-host interactions. His studies on TGFβ signaling also identified the RNA-binding protein Bicc1 and its self-polymerization in membrane-less organelles as regulators of mRNA translation and cell metabolism that cooperate with primary cilia to prevent cystic growth in renal tubules and in pancreatic and bile ducts.
Joachim Lingner
PhD at the Biocenter, University of Basel 1989-1992 (Supervisor: Walter Keller). Postdoc at the Howard Hughes Medical Institute, University of Colorado at Boulder 1993-1997 (Supervisor: Thomas Cech). Junior group leader at ISREC 1997-2001. Senior group leader at ISREC since 2002. Associate Professor at EPFL 2005-2008. Full Professor at EPFL since 2009. Honors: START-fellowship from the Swiss National Science Foundation in 1997; Friedrich Miescher Prize from the Swiss Society of Biochemistry in 2002; EMBO member in 2005; ERC advanced investigator grant in 2008.